Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Lung Cancer

  Free Subscription

Articles published in J Clin Oncol

Retrieve available abstracts of 82 articles:
HTML format

Single Articles

    November 2022
  1. YANG JT, Wijetunga NA, Pentsova E, Wolden S, et al
    Randomized Phase II Trial of Proton Craniospinal Irradiation Versus Photon Involved-Field Radiotherapy for Patients With Solid Tumor Leptomeningeal Metastasis.
    J Clin Oncol. 2022;40:3858-3867.
    PubMed     Abstract available

  2. SATTLER M, Salgia R
    Exploring the Next Frontier in Non-Small-Cell Lung Cancer With High MET and Mutated Epidermal Growth Factor Receptor.
    J Clin Oncol. 2022 Nov 3:JCO2202086. doi: 10.1200/JCO.22.02086.

  3. JOHNSON ML, Cho BC, Luft A, Alatorre-Alexander J, et al
    Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study.
    J Clin Oncol. 2022 Nov 3:JCO2200975. doi: 10.1200/JCO.22.00975.
    PubMed     Abstract available

    October 2022
  4. DE CASTRO G JR, Kudaba I, Wu YL, Lopes G, et al
    Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score >/= 1% in the KEYNOTE-042 Study.
    J Clin Oncol. 2022 Oct 28:JCO2102885. doi: 10.1200/JCO.21.02885.
    PubMed     Abstract available

  5. CAMIDGE DR, Barlesi F, Goldman JW, Morgensztern D, et al
    Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2022 Oct 26:JCO2200739. doi: 10.1200/JCO.22.00739.
    PubMed     Abstract available

  6. BRAHMER JR, Lee JS, Ciuleanu TE, Caro RB, et al
    Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer in CheckMate 227.
    J Clin Oncol. 2022 Oct 12:101200JCO2201503. doi: 10.1200/JCO.22.01503.
    PubMed     Abstract available

  7. WANG Z, Wu L, Li B, Cheng Y, et al
    Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non-Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01).
    J Clin Oncol. 2022 Oct 7:JCO2200727. doi: 10.1200/JCO.22.00727.
    PubMed     Abstract available

    September 2022
  8. LIN JJ, Gainor JF
    Selective Targeting of RET Fusions in Lung Cancer.
    J Clin Oncol. 2022 Sep 19:JCO2201644. doi: 10.1200/JCO.22.01644.

  9. DRILON A, Subbiah V, Gautschi O, Tomasini P, et al
    Selpercatinib in Patients With RET Fusion-Positive Non-Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial.
    J Clin Oncol. 2022 Sep 19:JCO2200393. doi: 10.1200/JCO.22.00393.
    PubMed     Abstract available

  10. ADOTEVI O, Vernerey D, Jacoulet P, Meurisse A, et al
    Safety, Immunogenicity, and 1-Year Efficacy of Universal Cancer Peptide-Based Vaccine in Patients With Refractory Advanced Non-Small-Cell Lung Cancer: A Phase Ib/Phase IIa De-Escalation Study.
    J Clin Oncol. 2022 Sep 7:JCO2200096. doi: 10.1200/JCO.22.00096.
    PubMed     Abstract available

    August 2022
  11. YUE D, Xu S, Wang Q, Li X, et al
    Updated Overall Survival and Exploratory Analysis From Randomized, Phase II EVAN Study of Erlotinib Versus Vinorelbine Plus Cisplatin Adjuvant Therapy in Stage IIIA Epidermal Growth Factor Receptor+ Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2022 Aug 26:JCO2200428. doi: 10.1200/JCO.22.00428.
    PubMed     Abstract available

  12. MIYAUCHI E, Morita S, Nakamura A, Hosomi Y, et al
    Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated EGFR.
    J Clin Oncol. 2022 Aug 12:JCO2102911. doi: 10.1200/JCO.21.02911.
    PubMed     Abstract available

  13. ARBOUR KC, Lito P
    Expanding the Arsenal of Clinically Active KRAS G12C Inhibitors.
    J Clin Oncol. 2022;40:2609-2611.

  14. OU SI, Janne PA, Leal TA, Rybkin II, et al
    First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRAS(G12C) Solid Tumors (KRYSTAL-1).
    J Clin Oncol. 2022;40:2530-2538.
    PubMed     Abstract available

  15. LIGIBEL JA, Bohlke K, May AM, Clinton SK, et al
    Exercise, Diet, and Weight Management During Cancer Treatment: ASCO Guideline.
    J Clin Oncol. 2022;40:2491-2507.
    PubMed     Abstract available

    July 2022
  16. SINGH N, Temin S, Baker S Jr, Blanchard E, et al
    Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline.
    J Clin Oncol. 2022 Jul 11:JCO2200825. doi: 10.1200/JCO.22.00825.
    PubMed     Abstract available

  17. SINGH N, Temin S, Baker S Jr, Blanchard E, et al
    Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline.
    J Clin Oncol. 2022 Jul 11:JCO2200824. doi: 10.1200/JCO.22.00824.
    PubMed     Abstract available

    June 2022
  18. MACK PC, Hirsch FR, Bunn PA, Minna JD, et al
    Longitudinal COVID-19 Vaccination-Induced Antibody Responses and Omicron Neutralization in Patients With Lung Cancer.
    J Clin Oncol. 2022 Jun 27:JCO2201136. doi: 10.1200/JCO.22.01136.

  19. VALANPARAMBIL RM, Carlisle J, Linderman SL, Akthar A, et al
    Antibody Response to COVID-19 mRNA Vaccine in Patients With Lung Cancer After Primary Immunization and Booster: Reactivity to the SARS-CoV-2 WT Virus and Omicron Variant.
    J Clin Oncol. 2022 Jun 27:JCO2102986. doi: 10.1200/JCO.21.02986.
    PubMed     Abstract available

    Strategies and End Points in the Development of Novel Immunotherapy Trials for Patients With Unresectable, Locally Advanced Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2022 Jun 20:JCO2200827. doi: 10.1200/JCO.22.00827.

  21. PASSARO A, Attili I, de Marinis F
    Neoadjuvant Chemotherapy Plus Immunotherapy in Early-Stage Resectable Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2022 Jun 17:JCO2200873. doi: 10.1200/JCO.22.00873.
    PubMed     Abstract available

  22. AGGARWAL C, Gyawali B
    Aumolertinib in EGFR-Mutant Lung Cancer: Will the Promise of Cost Disruption Ease Access?
    J Clin Oncol. 2022 Jun 9:JCO2200903. doi: 10.1200/JCO.22.00903.

  23. PEROL M, Swalduz A
    Lorlatinib in Frontline Therapy for ALK+ Advanced Non-Small-Cell Lung Cancer: Still a Matter of Debate?
    J Clin Oncol. 2022 Jun 9:JCO2200859. doi: 10.1200/JCO.22.00859.

  24. RECKAMP KL, Redman MW, Dragnev KH, Minichiello K, et al
    Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small-Cell Lung Cancer Previously Treated With Immunotherapy-Lung-MAP S1800A.
    J Clin Oncol. 2022 Jun 3:JCO2200912. doi: 10.1200/JCO.22.00912.
    PubMed     Abstract available

    May 2022
  25. SOLOMON BJ, Bauer TM, Ignatius Ou SH, Liu G, et al
    Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With ALK-Positive Advanced Non-Small-Cell Lung Cancer From the Phase III CROWN Study.
    J Clin Oncol. 2022 May 23:JCO2102278. doi: 10.1200/JCO.21.02278.
    PubMed     Abstract available

  26. RIVERA MP, Cupertino P, Henderson LM
    Complementary Approaches to Lung Cancer Detection in High-Risk Populations.
    J Clin Oncol. 2022 May 23:JCO2200494. doi: 10.1200/JCO.22.00494.

  27. LU S, Dong X, Jian H, Chen J, et al
    AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations.
    J Clin Oncol. 2022 May 17:JCO2102641. doi: 10.1200/JCO.21.02641.
    PubMed     Abstract available

  28. PROVENCIO M, Serna-Blasco R, Nadal E, Insa A, et al
    Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial).
    J Clin Oncol. 2022 May 16:JCO2102660. doi: 10.1200/JCO.21.02660.
    PubMed     Abstract available

  29. FALLET V, Sanchis-Borja M, Benusiglio PR, Cadranel J, et al
    Do Female BRCA2 Pathogenic Variant Carriers Have an Increased Risk of Lung Cancer?
    J Clin Oncol. 2022 May 12:JCO2200488. doi: 10.1200/JCO.22.00488.

    April 2022
  30. HERBST RS, Majem M, Barlesi F, Carcereny E, et al
    COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2022 Apr 22:JCO2200227. doi: 10.1200/JCO.22.00227.
    PubMed     Abstract available

    Lung Cancer Disparities Outcomes: The Urgent Need for Narrowing Care Gaps.
    J Clin Oncol. 2022 Apr 15:JCO2200321. doi: 10.1200/JCO.22.00321.

    March 2022
  32. PARK S, Ock CY, Kim H, Pereira S, et al
    Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2022 Mar 10:JCO2102010. doi: 10.1200/JCO.21.02010.
    PubMed     Abstract available

  33. OSAROGIAGBON RU, Liao W, Faris NR, Meadows-Taylor M, et al
    Lung Cancer Diagnosed Through Screening, Lung Nodule, and Neither Program: A Prospective Observational Study of the Detecting Early Lung Cancer (DELUGE) in the Mississippi Delta Cohort.
    J Clin Oncol. 2022 Mar 8:JCO2102496. doi: 10.1200/JCO.21.02496.
    PubMed     Abstract available

  34. PUJOL JL
    Durvalumab Induces Sustained Survival Benefit After Concurrent Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2022 Mar 3:JCO2200204. doi: 10.1200/JCO.22.00204.

    February 2022
  35. TSAO AS, Pass HI, Rimner A, Mansfield AS, et al
    New Era for Malignant Pleural Mesothelioma: Updates on Therapeutic Options.
    J Clin Oncol. 2022;40:681-692.
    PubMed     Abstract available

  36. STINCHCOMBE TE, Bradley JD
    Thoracic Oncology: Current Standard Therapy and Future Developments.
    J Clin Oncol. 2022;40:527-529.

  37. PISTERS K, Kris MG, Gaspar LE, Ismaila N, et al
    Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I-IIIA Completely Resected Non-Small-Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update.
    J Clin Oncol. 2022 Feb 15:JCO2200051. doi: 10.1200/JCO.22.00051.
    PubMed     Abstract available

  38. CHARLOT M, Stein JN, Damone E, Wood I, et al
    Effect of an Antiracism Intervention on Racial Disparities in Time to Lung Cancer Surgery.
    J Clin Oncol. 2022 Feb 14:JCO2101745. doi: 10.1200/JCO.21.01745.
    PubMed     Abstract available

  39. PIRES DA SILVA I, Ahmed T, McQuade JL, Nebhan CA, et al
    Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma.
    J Clin Oncol. 2022 Feb 10:JCO2101701. doi: 10.1200/JCO.21.01701.
    PubMed     Abstract available

  40. SPIGEL DR, Faivre-Finn C, Gray JE, Vicente D, et al
    Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2022 Feb 2:JCO2101308. doi: 10.1200/JCO.21.01308.
    PubMed     Abstract available

    Who Is MB and What Does She Want?
    J Clin Oncol. 2022;40:427-429.

    January 2022
  42. MAZIERES J, Lafitte C, Ricordel C, Greillier L, et al
    Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non-Small-Cell Lung Cancer Harboring HER2 Mutations: Results From the IFCT-1703 R2D2 Trial.
    J Clin Oncol. 2022 Jan 24:JCO2101455. doi: 10.1200/JCO.21.01455.
    PubMed     Abstract available

  43. COOPER AJ, Gainor JF
    Human Epidermal Growth Factor Receptor 2-Mutant Non-Small-Cell Lung Cancer: Continued Progress But Challenges Remain.
    J Clin Oncol. 2022 Jan 24:JCO2102550. doi: 10.1200/JCO.21.02550.

  44. FAHRMANN JF, Marsh T, Irajizad E, Patel N, et al
    Blood-Based Biomarker Panel for Personalized Lung Cancer Risk Assessment.
    J Clin Oncol. 2022 Jan 7:JCO2101460. doi: 10.1200/JCO.21.01460.
    PubMed     Abstract available

  45. DAI W, Feng W, Zhang Y, Wang XS, et al
    Patient-Reported Outcome-Based Symptom Management Versus Usual Care After Lung Cancer Surgery: A Multicenter Randomized Controlled Trial.
    J Clin Oncol. 2022 Jan 7:JCO2101344. doi: 10.1200/JCO.21.01344.
    PubMed     Abstract available

  46. PASSARO A, Brahmer J, Antonia S, Mok T, et al
    Managing Resistance to Immune Checkpoint Inhibitors in Lung Cancer: Treatment and Novel Strategies.
    J Clin Oncol. 2022 Jan 5:JCO2101845. doi: 10.1200/JCO.21.01845.
    PubMed     Abstract available

  47. CHAFT JE, Shyr Y, Sepesi B, Forde PM, et al
    Preoperative and Postoperative Systemic Therapy for Operable Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2022 Jan 5:JCO2101589. doi: 10.1200/JCO.21.01589.
    PubMed     Abstract available

  48. DONINGTON J, Schumacher L, Yanagawa J
    Surgical Issues for Operable Early-Stage Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2022 Jan 5:JCO2101592. doi: 10.1200/JCO.21.01592.
    PubMed     Abstract available

  49. TSUI DCC, Camidge DR, Rusthoven CG
    Managing Central Nervous System Spread of Lung Cancer: The State of the Art.
    J Clin Oncol. 2022 Jan 5:JCO2101715. doi: 10.1200/JCO.21.01715.
    PubMed     Abstract available

  50. PELLINI B, Chaudhuri AA
    Circulating Tumor DNA Minimal Residual Disease Detection of Non-Small-Cell Lung Cancer Treated With Curative Intent.
    J Clin Oncol. 2022 Jan 5:JCO2101929. doi: 10.1200/JCO.21.01929.
    PubMed     Abstract available

  51. BOGART JA, Waqar SN, Mix MD
    Radiation and Systemic Therapy for Limited-Stage Small-Cell Lung Cancer.
    J Clin Oncol. 2022 Jan 5:JCO2101639. doi: 10.1200/JCO.21.01639.
    PubMed     Abstract available

  52. TEMEL JS, Petrillo LA, Greer JA
    Patient-Centered Palliative Care for Patients With Advanced Lung Cancer.
    J Clin Oncol. 2022 Jan 5:JCO2101710. doi: 10.1200/JCO.21.01710.
    PubMed     Abstract available

  53. HIGGINS KA, Puri S, Gray JE
    Systemic and Radiation Therapy Approaches for Locally Advanced Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2022 Jan 5:JCO2101707. doi: 10.1200/JCO.21.01707.
    PubMed     Abstract available

  54. LEVY A, Mercier O, Le Pechoux C
    Indications and Parameters Around Postoperative Radiation Therapy for Lung Cancer.
    J Clin Oncol. 2022 Jan 5:JCO2101774. doi: 10.1200/JCO.21.01774.
    PubMed     Abstract available

  55. ZUGAZAGOITIA J, Paz-Ares L
    Extensive-Stage Small-Cell Lung Cancer: First-Line and Second-Line Treatment Options.
    J Clin Oncol. 2022 Jan 5:JCO2101881. doi: 10.1200/JCO.21.01881.
    PubMed     Abstract available

  56. DALY ME
    Inoperable Early-Stage Non-Small-Cell Lung Cancer: Stereotactic Ablative Radiotherapy and Rationale for Systemic Therapy.
    J Clin Oncol. 2022 Jan 5:JCO2101611. doi: 10.1200/JCO.21.01611.
    PubMed     Abstract available

  57. RECK M, Remon J, Hellmann MD
    First-Line Immunotherapy for Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2022 Jan 5:JCO2101497. doi: 10.1200/JCO.21.01497.
    PubMed     Abstract available

  58. TAN AC, Tan DSW
    Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations.
    J Clin Oncol. 2022 Jan 5:JCO2101626. doi: 10.1200/JCO.21.01626.
    PubMed     Abstract available

  59. JASPER K, Stiles B, McDonald F, Palma DA, et al
    Practical Management of Oligometastatic Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2022 Jan 5:JCO2101719. doi: 10.1200/JCO.21.01719.
    PubMed     Abstract available

    December 2021
  60. DALY ME, Singh N, Ismaila N, Antonoff MB, et al
    Management of Stage III Non-Small-Cell Lung Cancer: ASCO Guideline.
    J Clin Oncol. 2021 Dec 22:JCO2102528. doi: 10.1200/JCO.21.02528.
    PubMed     Abstract available

    November 2021
  61. LE X, Cornelissen R, Garassino M, Clarke JM, et al
    Poziotinib in Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial.
    J Clin Oncol. 2021 Nov 29:JCO2101323. doi: 10.1200/JCO.21.01323.
    PubMed     Abstract available

  62. DEVARAKONDA S, Li Y, Martins Rodrigues F, Sankararaman S, et al
    Genomic Profiling of Lung Adenocarcinoma in Never-Smokers.
    J Clin Oncol. 2021;39:3747-3758.
    PubMed     Abstract available

  63. LIU SY, Zhang JT, Wu YL
    What We Have Learned From Adjuvant Therapy for Resected EGFR-Mutant Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2021 Nov 18:JCO2102443. doi: 10.1200/JCO.21.02443.

  64. TADA H, Mitsudomi T, Misumi T, Sugio K, et al
    Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIA Non-Small-Cell Lung Cancer With EGFR Mutation (IMPACT).
    J Clin Oncol. 2021 Nov 2:JCO2101729. doi: 10.1200/JCO.21.01729.
    PubMed     Abstract available

  65. SOULIERES D, Gelmon KA
    Sotorasib: Is Maximum Tolerated Dose Really the Issue at Hand?
    J Clin Oncol. 2021;39:3427-3429.

    October 2021
  66. BROWN PD, Parsons MW, Rusthoven CG, Gondi V, et al
    Hippocampal Avoidance Prophylactic Cranial Irradiation: A New Standard of Care?
    J Clin Oncol. 2021;39:3093-3096.

    September 2021
  67. ELAMIN YY, Robichaux JP, Carter BW, Altan M, et al
    Poziotinib for Patients With HER2 Exon 20 Mutant Non-Small-Cell Lung Cancer: Results From a Phase II Trial.
    J Clin Oncol. 2021 Sep 22:JCO2101113. doi: 10.1200/JCO.21.01113.
    PubMed     Abstract available

  68. DRILON A, Duruisseaux M, Han JY, Ito M, et al
    Clinicopathologic Features and Response to Therapy of NRG1 Fusion-Driven Lung Cancers: The eNRGy1 Global Multicenter Registry.
    J Clin Oncol. 2021;39:2791-2802.
    PubMed     Abstract available

    August 2021
  69. RAMALINGAM SS, Novello S, Guclu SZ, Bentsion D, et al
    Veliparib in Combination With Platinum-Based Chemotherapy for First-Line Treatment of Advanced Squamous Cell Lung Cancer: A Randomized, Multicenter Phase III Study.
    J Clin Oncol. 2021 Aug 26:JCO2003318. doi: 10.1200/JCO.20.03318.
    PubMed     Abstract available

  70. RODRIGUEZ DE DIOS N, Counago F, Murcia-Mejia M, Rico-Oses M, et al
    Randomized Phase III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small-Cell Lung Cancer (PREMER): A GICOR-GOECP-SEOR Study.
    J Clin Oncol. 2021 Aug 11:JCO2100639. doi: 10.1200/JCO.21.00639.
    PubMed     Abstract available

  71. PARK K, Haura EB, Leighl NB, Mitchell P, et al
    Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study.
    J Clin Oncol. 2021 Aug 2:JCO2100662. doi: 10.1200/JCO.21.00662.
    PubMed     Abstract available

  72. SHU CA, Cascone T
    What Is Neo? Chemoimmunotherapy in the Neoadjuvant Setting for Resectable Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2021 Aug 2:JCO2101446. doi: 10.1200/JCO.21.01446.

    July 2021
  73. ROTHSCHILD SI, Zippelius A, Eboulet EI, Savic Prince S, et al
    SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial.
    J Clin Oncol. 2021 Jul 12:JCO2100276. doi: 10.1200/JCO.21.00276.
    PubMed     Abstract available

    June 2021
  74. REMON J, Hendriks LEL, Besse B
    Paving the Way for Long-Term Survival in Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2021 Jun 8:JCO2100760. doi: 10.1200/JCO.21.00760.

  75. PASSIGLIA F, Cinquini M, Bertolaccini L, Del Re M, et al
    Benefits and Harms of Lung Cancer Screening by Chest Computed Tomography: A Systematic Review and Meta-Analysis.
    J Clin Oncol. 2021 Jun 2:JCO2002574. doi: 10.1200/JCO.20.02574.
    PubMed     Abstract available

    May 2021
  76. GILLESSEN S, Sauve N, Collette L, Daugaard G, et al
    Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium.
    J Clin Oncol. 2021;39:1563-1574.
    PubMed     Abstract available

    April 2021
  77. RECK M, Rodriguez-Abreu D, Robinson AG, Hui R, et al
    Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score >/= 50.
    J Clin Oncol. 2021 Apr 19:JCO2100174. doi: 10.1200/JCO.21.00174.
    PubMed     Abstract available

    March 2021
  78. WAQAR SN, Govindan R
    Adjuvant Therapy With EGFR Tyrosine Kinase Inhibitors: Tempering Great Expectations With Realism.
    J Clin Oncol. 2021;39:697-700.

  79. ZHONG WZ, Wang Q, Mao WM, Xu ST, et al
    Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial.
    J Clin Oncol. 2021;39:713-722.
    PubMed     Abstract available

    February 2021
  80. EWER MS, Tekumalla SH, Walding A, Atuah KN, et al
    Cardiac Safety of Osimertinib: A Review of Data.
    J Clin Oncol. 2021;39:328-337.
    PubMed     Abstract available

    January 2021
  81. GYAWALI B, West HJ
    Lessons From ADAURA on Adjuvant Cancer Drug Trials: Evidence, Ethics, and Economics.
    J Clin Oncol. 2021;39:175-177.

    December 2020
  82. BEKELMAN JE, Gupta A, Fishman E, Debono D, et al
    Association Between a National Insurer's Pay-for-Performance Program for Oncology and Changes in Prescribing of Evidence-Based Cancer Drugs and Spending.
    J Clin Oncol. 2020;38:4055-4063.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.